Low Residue Diet Study in Mitochondrial Disease (LRD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03388528|
Recruitment Status : Recruiting
First Posted : January 3, 2018
Last Update Posted : January 3, 2018
Slow movement of patients guts is referred to as intestinal dysmotility, and is increasingly recognised as a debilitating manifestation of mitochondrial disease both in adults and children.
To date, symptoms of slow gut movements have been managed with laxatives and drugs that increase movement of the guts with variable results. A low residue diet is a form of low fibre diet (<10g fibre per day) that is used to minimise symptoms of poor movement of the guts. This reduces fecal volume and bulk, and hence gut workload, ensuring limited bowel activity and colonic rest. It has been shown to be well accepted in other conditions associated with slow gut movements. However, its role in patients with mitochondrial disease is unknown. The investigators are particularly interested in:
- Does a low residue diet (low fibre) cause a change in the number of stools per week and stool consistency?
- Is a low residue diet tolerated well and easy to comply with?
- Does a low residue diet reduce gut symptoms of abdominal pain, bloating, and constipation?
- Does a low residue diet improve quality of life and disease burden?
- Does a low residue diet affect the bacteria in the gut?
- Can we prove by X-ray that movement of food through the gut is slowed in patients with mitochondrial disease, and whether a low residue diet alters the speed of movement of food through the gut?
- Can a low residue diet change patients physical activity levels?
- Does a low reside diet change dietary patterns and food intake?
- Does a low residue diet alter anthropometrics, such as weight, body mass index and waist to hit ratio?
- Can a low residue diet improve kidney and liver function and lipid profile in blood samples?
The investigators hope that by looking at these areas that a low residue diet may be able to improve patients slow gut movements, health, quality of life and disease burden.
|Condition or disease||Intervention/treatment||Phase|
|Mitochondrial Diseases||Dietary Supplement: Low Residue Diet Intervention||Not Applicable|
Intestinal dysmotility is increasingly recognised as a debilitating manifestation of mitochondrial disease both in adults and children (1). It is a frequent symptom of other neurological conditions including Cerebral Palsy, Multiple Sclerosis and Parkinson's Disease. Symptoms of intestinal dysmotility are often overlooked and frequently under-diagnosed in its early stages.
Indeed, in its most severe form, intestinal dysmotility may manifest as intestinal pseudo obstruction (IPO), characterised by a clinical picture suggestive of mechanical obstruction, exemplifying the need for early detection and management. To date, symptoms of intestinal dysmotility in slow transit time constipation, limited fluid and calorie intake, weight loss, and small intestinal bacterial overgrowth and in severe cases intestinal pseudo obstruction (2, 3). Moreover, the bacteria that reside within the gastrointestinal (GI) tract compete for nutrients, contributing to weight loss due to malabsorption of fat (4), protein and carbohydrates (5, 6), vitamin (7-11) and iron deficiency (12) are often evident. Further problems include poor digestion and absorption food, an impaired immune system, and an impaired drug absorption ability, all of which influence patient health, quality of life and increases National Health Service (NHS) costs.
A low residue diet is a form of low fibre diet (<10g fibre per day) that is used to minimise symptoms of intestinal dysmotility by reducing faecal volume and bulk and hence bowel workload, ensuring limited bowel activity and colonic rest. It has been shown to be both tolerable and efficacious in other conditions associated with intestinal dysmotility; however, its role in patients with mitochondrial disease and intestinal dysmotility, is unknown.
This feasibility study proposes to systematically gather data on whether a low residue diet is tolerable and has an effect on intestinal dysmotility and health-related quality of life in in patients with mitochondrial disease.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial Clinics for Research and Service in Themed Assessments (CRESTA) clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle|
|Masking:||None (Open Label)|
|Official Title:||Phase II Feasibility Study of the Efficacy and Acceptability of a Low Residue Diet in Adult Patients With Mitochondrial Disease|
|Actual Study Start Date :||September 8, 2017|
|Estimated Primary Completion Date :||September 7, 2018|
|Estimated Study Completion Date :||September 7, 2018|
Experimental: Treatment Group
This is a single arm study where forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial CRESTA clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle. All forty patients will be assessed prior to and following a 12 week low residue diet study intervention.
Dietary Supplement: Low Residue Diet Intervention
All patients will be provided with a LRD plan (< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
- Assess tolerability of a Low Residue Diet (LRD) in mitochondrial patients [ Time Frame: Change from baseline to 12 weeks ]Tolerability of the LRD will be assessed using food diaries
- Stool Frequency and consistency [ Time Frame: Change from baseline to 12 weeks ]
Assess stool consistency according to the Bristol Stool Form scale. Patients will select from the following to describe their stool consistency:
Type 1: Separate hard lumps, like nuts Type 2: Sausage-like but lumpy Type 3: Like a sausage but with cracks in the surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear-cut edges Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces
- Gastrointestinal Dysmotility [ Time Frame: Change from baseline to 12 weeks ]To determine the impact of a LRD on GI dysmotility symptoms using Assessment of Constipation-Symptom (PAC-SYM) questionnaire.
- Disease Burden [ Time Frame: Change from baseline to 12 weeks ]
To determine the effect of LRD on patients Disease burden as assessed by the Newcastle Mitochondrial Disease Adult Scale (NMDAS) disease burden and quality of life. This is a questionnaire developed and validated by Wellcome Centre for Mitochondrial Research, Newcastle upon Tyne. This is a scored questionnaire that encompasses questions on patient's disease burden encompassing:
Current Function: Vision with usual glasses or contact lenses; Migraine Headaches; Seizures; Stroke like episodes; Encephalopathic Episodes; Gastro-intestinal symptoms; Diabetes mellitus; Respiratory muscle weakness and Cardiovascular system.
Current Clinical Assessment: Visual acuity; Ptosis; Chronic Progressive External Ophthalmoplegia; Dysphonia/Dysarthria; Myopathy; Cerebellar ataxia; Neuropathy; Pyramidal Involvement; Extrapyramidal and Cogitation.
These are all included under the NMDAS questionnaire and are used by clinical care teams to help determine patient's current disease burden.
- Gut Microbiome changes [ Time Frame: Change from baseline to 12 weeks ]Assess effect of a LRD on gut metagenomics
- Food Intake [ Time Frame: Change from baseline to 12 weeks ]To assess the impact of a LRD on food intake (Food Frequency Questionnaire (FFQ) will be completed for 72 hours (1 day over the weekend and 2 days during the week).
- Colonic Transit Time [ Time Frame: Change from baseline to 12 weeks ]Colonic transit time (CTT) as assessed by plain abdominal X-ray following ingestion of oral colonic marker ingestion.
- Physical Activity [ Time Frame: Change from baseline to 12 weeks ]Activity level (GeneActiv 7-10 days).
- Biochemistry [ Time Frame: Change from baseline to 12 weeks ]The Biochemistry department in the Royal Victoria Infirmary in Newcastle upon Tyne will be provided with whole blood. Using this they will measures liver enzymes (alanine transaminase, aspartate aminotransferase, gamma-glutamyl transpeptide), alkaline phosphatase, albumin, bilirubin, lipid profile and C-Peptide tests.
- Gastrointestinal Health [ Time Frame: Change from baseline to 12 weeks ]To determine the impact of a LRD on patient GI symptoms using the Gastrointestinal Quality‐of‐Life Index. This includes defecation characteristics including laxative use and reported abdominal symptoms categorized as pain or cramps and bloating or flatulence according to five classifications (1, none; 2, mild; 3, moderate; 4, severe; or 5, very severe).
- Anthropometrics [ Time Frame: Change from baseline to 12 weeks ]Weight (kg)
- Physical Measurements [ Time Frame: Change from baseline to 12 weeks ]Body Mass Index
- Physical Dimensions [ Time Frame: Change from baseline to 12 weeks ]Waist to hip ratio (inches)
- Haematology [ Time Frame: Change from baseline to 12 weeks ]The Haematology department in the Royal Victoria Infirmary in Newcastle upon Tyne will be provided with whole blood. Using this they will provide a Full blood count, Haematocrit screen, Ferritin, Vitamin B12, HbA1c and Folate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03388528
|Contact: Grainne S Gorman, MD||0191 20 firstname.lastname@example.org|
|Contact: David Houghton, PhD||0191 208 email@example.com|
|Newcastle upon Tyne, Tyne And Wear, United Kingdom, NE2 4HH|
|Contact: David Houghton, PhD 07729221941 firstname.lastname@example.org|
|Contact: Paula Hynd, BSc 0191 208 3084 email@example.com|
|Principal Investigator:||Grainne S Gorman, MD||Newcastle University|